Prediction of resistance to poly(ADP-ribose) polymerase (PARP) inhibitors with BRCA1/BRCA2 mutational status has resulted in FDA-approved tests for PCa from Myriad Genetics and FoundationOne [107]. This evidence concerns the gene BRCA2 and posterior cortical atrophy.